Ascendis Pharma A/S
243.37USD
+0.3800 (+0.16%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on ASND.
Revenue
| (EUR) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 51.2M | 266.7M | 363.6M | 720.1M | 1.4B | 2.0B |
| Q1 | — | — | — | — | 246.6M | — |
| Q2 | — | — | — | 158.0M | 339.3M | — |
| Q3 | — | — | — | 213.6M | 367.1M | — |
| Q4 | — | — | — | 247.5M | 414.5M | — |
Revenue
| (EUR) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | -10.40 | -8.55 | -6.53 | -3.76 | 11.32 | 7.98 |
| Q1 | — | — | — | — | 9.75 | — |
| Q2 | — | — | — | -.820 | 2.83 | — |
| Q3 | — | — | — | -1.00 | .940 | — |
| Q4 | — | — |
Fiscal period: Reported, Estimated. Reported figures: Yahoo Finance (limited history). Estimates are sell-side consensus for periods that have not reported. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
Revenue to net income
| — |
| -.550 |
| 1.15 |
| — |
Debt level and coverage